Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + azacitidine vs decitabine + CAG in elderly relapsed/refractory AML
ChiCTR2600121428Phase 4Completed
- Sponsor
- Shanghai Jing'an District Beizhan Hospital
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of venetoclax, azacitidine and decitabine in acute myeloid leukemia (AML) (2 arms), sponsored by Shanghai Jing'an District Beizhan Hospital. Primary endpoints: complete remission rate and objective response rate. Started Mar 2026; status: completed.
02
Drugs
venetoclaxazacitidinedecitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2600121428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121428.